|
|
Volumn 352, Issue 25, 2005, Pages 2573-2576
|
|
Torcetrapib and atorvastatin - Should marketing drive the research agenda?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATORVASTATIN;
CHOLESTEROL ESTER TRANSFER PROTEIN;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
LIPID;
TORCETRAPIB;
CARRIER PROTEIN;
CETP PROTEIN, HUMAN;
GLYCOPROTEIN;
HEPTANOIC ACID DERIVATIVE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
HYPOCHOLESTEROLEMIC AGENT;
PYRROLE DERIVATIVE;
QUINOLINE DERIVATIVE;
ATHEROSCLEROTIC PLAQUE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CONCENTRATION (PARAMETERS);
DRUG COST;
DRUG EFFECT;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG MECHANISM;
DRUG STRUCTURE;
FOOD AND DRUG ADMINISTRATION;
HEART DISEASE;
HEART INFARCTION;
HUMAN;
INTRAVASCULAR ULTRASOUND;
PATIENT CARE;
PHYSICIAN;
PRESCRIPTION;
PRIORITY JOURNAL;
REVIEW;
STROKE;
TABLET;
ARTICLE;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
BLOOD;
CHEMICAL STRUCTURE;
CHEMISTRY;
CORONARY ARTERY ATHEROSCLEROSIS;
DRUG ANTAGONISM;
DRUG APPROVAL;
DRUG COMBINATION;
DRUG INDUSTRY;
ECONOMICS;
HEALTH CARE AND PUBLIC HEALTH;
MARKETING;
METHODOLOGY;
STANDARD;
UNITED STATES;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
HEALTH CARE AND PUBLIC HEALTH;
ANTICHOLESTEREMIC AGENTS;
CARRIER PROTEINS;
CHOLESTEROL ESTER TRANSFER PROTEINS;
CHOLESTEROL, HDL;
CLINICAL TRIALS;
CORONARY ARTERIOSCLEROSIS;
DRUG APPROVAL;
DRUG COMBINATIONS;
DRUG INDUSTRY;
GLYCOPROTEINS;
HEPTANOIC ACIDS;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
MARKETING;
MOLECULAR STRUCTURE;
PYRROLES;
QUINOLINES;
RESEARCH DESIGN;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 20544454535
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp058075 Document Type: Review |
|
Times cited : (28)
|
|
References (5)
|
